Weed (BUDZ) Asset Writedowns and Impairment (2019)
Weed's (BUDZ) quarterly Asset Writedowns and Impairment came in at $499695.0 in Q4 2019.
Weed (BUDZ) Asset Writedowns and Impairment (2019) Analysis & Trends
Weed's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $499695.0 for Q4 2019.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $499695.0 in Q4 2019; TTM through Sep 2020 was $499695.0, a N/A change from a year earlier, with the FY2019 full-year figure at $499695.0, up 55.37% from the prior year.
- Asset Writedowns and Impairment was little changed at $499695.0 in Q4 2019 per BUDZ's latest filing.
- Across five years, Asset Writedowns and Impairment topped out at $499695.0 in Q4 2019 and bottomed at $499695.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Weed | 3.10 Mn | 3.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 499,695.00 |
| Dec 31, 2019 | 499,695.00 |